Developing targeted therapies for Celiac Disease and Type 1 Diabetes


Antigen-specific Immune Tolerance

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, celiac disease and type-1 diabetes.

Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with celiac disease and type-1 diabetes by leveraging the immunotechnology expertise of Anokion.




Science & Technology

At Kanyos, we are focused on translating the antigen-specific immune tolerance technology developed at Anokion to develop targeted treatments for celiac disease and type-1 diabetes.


Join Our Team

We strive to create a stimulating and professional environment
to enable realization of such a mission.




Kanyos Labs (348).jpg